Dilutive Share Sale
The stock is selling off violently after the company priced a large new share offering at $3.25, a steep discount that dilutes existing holders and signals a cash raise ahead of the news.
Sources: https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-prices-61-54m-shares-of-class-a-common-stock-at-3-25-thefly-news, https://biotechdistilled.substac
Previous verdicts for RXRX
- AI Search: Needham Buy Reiteration and Cathie Wood Buying Lift Recursion — 2026-10-19
- AI Search: RXRX slips slightly as technical selling outweighs CEO Form 4 filing — 2026-10-13
- AI Search: ARK Invest Stake Ignites Sharp Rally in Recursion Pharmaceuticals — 2026-10-09
- AI Search: Recursion Pharmaceuticals Slips as Losses and Insider Sales Weigh — 2026-10-08
- AI Search: RXRX Slides Aggressively as Profit-Taking Follows Short-Covering Spike — 2026-10-06
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works